GRAY: Graybug Vision, Inc. - Summary | Jitta
Jitta Wealth
NEW
Log in
Sign up
×
Log in

Graybug Vision, Inc.

NASDAQ:GRAY

SummaryFactSheetFinancial
Notice
Stock data is unavailable or the company’s delisted.
Price
$5.50
Loss Chance
58.0%
1.50JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Related
The Central and Eastern Europe Fund
NYSE:CEE
4.41
$8.07
53.66%
United States Commodity Index Funds Trust - United States Copper Index Fund
NYSE:CPER
3.32
$20.84
38.04%
Invesco DB Commodity Index Tracking Fund
NYSE:DBC
2.67
$25.19
16.43%
Guggenheim Strategic Opportunities Fund
NYSE:GOF
4.18
$17.02
14.82%
iShares S&P GSCI Commodity-Indexed Trust
NYSE:GSG
2.61
$21.72
28.20%
Jitta Factors
Growth Opportunity (13)
Recent Business Performance (33)
Financial Strength (33)
Return to Shareholders (0)
Competitive Advantage (8)
Jitta Signs
Recent Business PerformanceEarning Growth Last Quarter (YoY)
SG&A to SalesDecreasing Every Year
Cash Conversion CycleLess than 30 days
Recent IPOLess than 3 years
CapExVery High
SG&A to SalesIncreasing Every Year
Key Stats
Jitta Score
Jitta Line
1.50
100.00%
2.34
229.72%
2.34
229.72%
4.41
53.66%
3.32
38.04%
2.67
16.43%
COMPANY DESCRIPTION
As of March 20, 2023, Graybug Vision, Inc. was acquired by CalciMedica, Inc., in a reverse merger transaction. Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company’s lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.
www.graybug.vision
About UsCareersHelp CenterLibraryTermsPrivacyContact UsPress

Jitta Dot Com Co., Ltd. is the owner of the copyright of JITTA SCORE, JITTA LINE, JITTA SIGNS, JITTA FACTORS, JITTA LOSS CHANCE and JITTA RANKING. By accessing or using Jitta, you agree to comply with our Terms of Use and agree not to redistribute the information.

All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Any historical returns, backtest statistics or probability projections may not reflect future performance. Neither Jitta nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Fundamental data of companies, historical data, daily updates, financial statements, dividend data and index data are provided by S&P Global Market Intelligence. All stock prices are updated at the end of the day.